News

Achillion continues to expect the transaction to close in the first half of 2020, subject to expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust

Kadcyla will be used to treat the patients who have residual invasive disease in the breast and/or lymph nodes after neoadjuvant (before surgery) taxane-based and HER2-targeted therapy. Kadcyla

The collaboration will utilize the MORPHEUS Phase 1b/2 platform for rapid and efficient combination development, with upfront randomization versus control groups, in two studies: Third-line metastatic CRC: two

Padcev, a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4 protein, has secured approval under the FDA’s Accelerated Approval Program based on tumour response rate. Nectin-4, which

As published in The New England Journal of Medicine (NEJM), results from the BEACON CRC trial showed improvements in overall survival (OS) and objective response rates (ORR) for

The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 9-4 in favour of approving Keytruda for the new indication. The anti-PD-1 therapy has already been approved in the US

In the study, participants taking AMX0035 had a statistically significant slowing of ALS disease progression as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) compared to placebo (p<0.05),

The status has been provided to DCR-A1AT based on a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA). A1AT deficiency

The latest approval means that XTANDI is indicated for the treatment of three distinct forms of advanced prostate cancer that include non-metastatic and metastatic castration-resistant prostate cancer (CRPC),